Prudential Financial
PTGX icon

Prudential Financial’s Protagonist Therapeutics PTGX Stock Holding History

Prudential Financial’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Sell
85,180
-10,055
-11% -$1.05M 0.01% 677
2026
Q1 		$10M Sell
95,235
-15,125
-14% -$1.34M 0.01% 631
2025
Q4 		$9.64M Sell
110,360
-16,043
-13% -$1.31M 0.01% 636
2025
Q3 		$8.4M Buy
126,403
+48,995
+63% +$2.78M 0.01% 697
2025
Q2 		$4.28M Buy
77,408
+19,050
+33% +$914K 0.01% 1004
2025
Q1 		$2.82M Sell
58,358
-1,640
-3% -$68.7K ﹤0.01% 1127
2024
Q4 		$2.32M Sell
59,998
-800
-1% -$34.9K ﹤0.01% 1233
2024
Q3 		$2.74M Buy
+60,798
New +$2.46M ﹤0.01% 1297
2023
Q2 		– Sell
-67,293
Closed -$1.55M – 2691
2023
Q1 		$1.55M Buy
+67,293
New +$1.13M ﹤0.01% 1497
2022
Q2 		– Sell
-22,993
Closed -$544K – 2735
2022
Q1 		$544K Sell
22,993
-7,112
-24% -$200K ﹤0.01% 2168
2021
Q4 		$1.03M Sell
30,105
-190
-0.6% -$6.01K ﹤0.01% 1867
2021
Q3 		$537K Buy
30,295
+450
+2% +$19.2K ﹤0.01% 2117
2021
Q2 		$1.34M Sell
29,845
-3,770
-11% -$124K ﹤0.01% 1677
2021
Q1 		$871K Sell
33,615
-10,210
-23% -$258K ﹤0.01% 1898
2020
Q4 		$884K Sell
43,825
-11,190
-20% -$241K ﹤0.01% 1810
2020
Q3 		$1.08M Sell
55,015
-12,290
-18% -$231K ﹤0.01% 1609
2020
Q2 		$1.19M Sell
67,305
-5,035
-7% -$63.2K ﹤0.01% 1572
2020
Q1 		$511K Buy
72,340
+20,650
+40% +$155K ﹤0.01% 1905
2019
Q4 		$365K Buy
+51,690
New +$513K ﹤0.01% 2149
2018
Q3 		– Sell
-12,100
Closed -$81K – 2463
2018
Q2 		$81K Sell
12,100
-1,470
-11% -$11.3K ﹤0.01% 2398
2018
Q1 		$116K Buy
+13,570
New +$256K ﹤0.01% 2290

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Prudential Financial's PTGX Position: Q2 2026 in Review

Prudential Financial reduced its Protagonist Therapeutics (PTGX) stake by 11% in Q2 2026, selling an estimated $1.05M and leaving 85,180 shares worth $10.4M. The position accounts for 0.01% of the portfolio, ranked #677.

Prudential Financial first reported a position in PTGX in Q1 2018 and has held it in 21 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Prudential Financial held 85,180 shares of Protagonist Therapeutics worth $10.4M as of Q2 2026.
  • Prudential Financial sold 10,055 Protagonist Therapeutics shares in Q2 2026, an estimated $1.05M.
  • Protagonist Therapeutics made up 0.01% of Prudential Financial's portfolio in Q2 2026, its #677 holding.
  • Prudential Financial first reported a position in Protagonist Therapeutics in Q1 2018 and has held it in 21 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.